Sight Diagnostics Announces Strategic Hires to Expand US and Global Presence, Bringing Improved Blood Testing to Millions

Sight Diagnostics, the company working to provide patients with lab-grade blood testing results in minutes, today announces two strategic hires to drive global growth. The expansion of the team supports Sight’s clinical progress in the US as the company recently completed clinical trials and is working toward commercialization.

Sight is the maker of OLO, a blood analyzer that performs diagnostics from two drops of blood with the goal of improving efficiencies and the patient experience. Using a patented method of “digitizing” blood samples, Sight’s proprietary technology captures 1,000 highly detailed images of a finger prick sample, which is then analyzed by its machine learning algorithms. The company first deployed its technology to detect Malaria and have delivered nearly 1 million tests in 24 countries. Now, Sight has applied the same clinically-tested technology for Complete Blood Counts (CBCs), the most commonly ordered type of blood test, and is exploring other applications to improve diagnostics and patient care.

Assi Gol, Sight’s new Chief Commercial Officer, will lead the company’s global growth. As the head of Sight’s commercial team, he collaborates with partners across the healthcare space to accelerate Sight’s impact on patients’ lives. Before joining the executive team, he served on Sight’s advisory board and has supported the company since its founding in 2011. Previously, Assi served as the Data Intelligence Director at Shop Direct, the UK’s second-largest pure-play online retailer. He also spent seven years at McKinsey & Company in London and Tel-Aviv, helping companies accelerate their growth with creative and strategic thinking, while also pursuing his MBA at INSEAD.

“After years of R&D, we’re thrilled to introduce our technology to the US market and impact on millions of patients’ lives,” said Gol. “This is an exciting moment for the company. We’ve opened new offices in London and Silicon Valley with the goal of attracting top talent who feel passionate about making big improvements in healthcare.”

Based in Sight’s new Palo Alto office, Noga Eshed-Baror, the company’s new General US Manager, will lead all US efforts, including commercialization and hiring. Eshed-Baror, a graduate of the Stanford Business School, brings more than 10 years of business experience to Sight, having led projects at both Google and McKinsey. 

The US represents an enormous opportunity for Sight -- it remains the largest medical device market in the world -- and is expected to grow to $208 billion by 2023. Sight has already completed clinical trials in early 2019 at Boston Children’s Hospital and Columbia University Irving Medical Center to study OLO’s clinical performance. The results from the trials have been submitted to the FDA for FDA 510(k) clearance, which would allow OLO to be used in qualified US laboratories. 

“Current blood testing methods are expensive and the process for both the patient and health professional is laborious,” said Eshed-Baror. “Sight’s groundbreaking technology and exceptional team have enormous potential to transform healthcare in the US and globally, and I’m thrilled to be part of this next chapter.”

About Sight Diagnostics

The faster we diagnose, the faster we can treat. At Sight Diagnostics, we aim to improve health through faster and pain-free diagnostic testing. Sight’s latest analyzer, OLO, performs a Complete Blood Count, the most commonly ordered blood test, in minutes and has a compact design to improve usability. Sight’s method was developed over a decade of research. Our analyzers create a digital version of your blood, by capturing 1,000 highly detailed images of a finger prick sample, which is then interpreted by our proprietary algorithms. Sight’s first product was focused on detecting Malaria, used in 24 countries, and has delivered almost 1 million tests to date. At Sight, exceptional individuals work together to achieve extraordinary things. We have rapidly growing offices in London, Silicon Valley, and Tel Aviv. 

Learn more at sightdx.com.

Sight’s OLO is approved and available for clinical use through the CE Mark registration in the EU and is currently under FDA review for 510(k) clearance and is not yet available for sale in the United States.

Contact Information

Emma Baron

Senior Account Executive

VSC for Sight Diagnostics

emmab@vsc.co